Results 41 to 50 of about 129,945 (312)

Pazopanib Combined With Vincristine and Irinotecan in Relapsed Wilms Tumor: Encouraging Outcomes in a Heavily Pretreated Pediatric Cohort

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background While Wilms tumor (WT) typically has a favorable prognosis, relapsed cases—especially those with high‐risk histology—remain therapeutically challenging after intensive frontline therapy. The combination of vincristine and irinotecan has demonstrated activity in pediatric solid tumors, and pazopanib, a multi‐targeted tyrosine kinase ...
Maria Debora De Pasquale, Alessandro Crocoli, Giuseppe Maria Milano, Pierluigi Di Paolo, Francesca Diomedi Camassei, Ida Russo, Annalisa Serra   +6 more
wiley   +1 more source

Rapid detection of acetolactate synthase inhibitor–resistant weeds using novel full-spectrum imaging and a hyperparameter-tuned convolutional neural network

Weed Technology
Herbicide-resistant weeds are fast becoming a substantial global problem, causing significant crop losses and food insecurity. Late detection of resistant weeds leads to increasing economic losses.
Pauline Victoria Estrada, John Benedict Estrada, Jennifer Valdez-Herrera, Anil Shrestha   +3 more
doaj   +1 more source

GSK-3β Inhibitor Alsterpaullone Attenuates MPP+-Induced Cell Damage in a c-Myc-Dependent Manner in SH-SY5Y Cells

Frontiers in Cellular Neuroscience, 2018
Mitochondrial dysfunction plays significant roles in the pathogenesis of Parkinson’s Disease (PD). The inactivation of c-Myc, a down-stream gene of Wnt/β-catenin signaling, may contribute to the mitochondria dysfunction.
Jiancai Wang, Yuqian Li, Li Gao, Fengqi Yan, Guodong Gao, Lihong Li   +5 more
doaj   +1 more source

Nutritional and Behavioral Intervention for Long‐Term Childhood Acute Leukemia Survivors With Metabolic Syndrome

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Metabolic syndrome (MetS) is a common complication in survivors of childhood acute lymphoblastic and myeloid leukemia (AL), and a major risk factor for premature cardiovascular disease, type‐2‐diabetes, and metabolic dysfunction‐associated steatotic liver disease (MASLD).
Visentin Sandrine, Béliard Sophie, Renard Cécile, Caussy Cyrielle, Hamidou Zeinab, Romano David, Gacem Mélanie, Petit Arnaud, Saultier Paul, Borentain Patrick, Michel Gérard   +10 more
wiley   +1 more source

Brainiac Caspases: Beyond the Wall of Apoptosis [PDF]

, 2019
For the last two decades, caspases, a family of cysteine-aspartic proteases, have evolved from being considered solely as regulators of apoptosis or inflammation to having a wider range of functions.
Alonso Bellido, Isabel María, Burguillos García, Miguel Ángel, Espinosa Oliva, Ana María, García Revilla, Juan   +3 more
core   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura, Kentaro Ueno, Takuro Nishikawa, Yoshihiro Takahashi, Koji Nakae, Yasuhiro Okamoto   +5 more
wiley   +1 more source

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Frontiers in Neurology, 2019
Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS.
Paul Lingor, Paul Lingor, Markus Weber, William Camu, Tim Friede, Reinhard Hilgers, Andreas Leha, Christoph Neuwirth, René Günther, René Günther, Michael Benatar, Magdalena Kuzma-Kozakiewicz, Helen Bidner, Christiane Blankenstein, Roberto Frontini, Albert Ludolph, Jan C. Koch, The ROCK-ALS Investigators, Shahram Attarian, Mathias Bähr, Matthias Boentert, Nathalie Braun, Philippe Corcia, Isabell Cordts, Marcus Deschauer, Thorsten Grehl, Julian Grosskreutz, Andreas Hermann, Josua Kuttler, Teresa Lengenfeldt, Fabian Maass, Thomas Meyer, Susanne Petri, Yvonne Remane, Jens Schmidt, Joachim Schuster, Marie-Hélène Soriani, Jeffrey Statland, Jochen Weishaupt, Daniel Zeller, Eirini Zielke   +40 more
doaj   +1 more source

Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio‐Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis, but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available.
Vicente Santa‐Maria Lopez, Anna Felip‐Badia, Marina Caballero‐Bellon, Nazaret Sanchez‐Sierra, Alicia Castañeda, Moira Garraus, Maite Gorostegui, Margarida Simão‐Rafael, Juan Pablo Muñoz, Marta Perez‐Somarriba, Salvador Mañe, Mariana Cecilia Planells, Sara Perez‐Jaume, Jaume Mora   +13 more
wiley   +1 more source

Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Approximately 10% of patients with Ewing sarcoma (EwS) have pathogenic germline variants. Here, we report two cases: first, a novel germline pathogenic variant in partner and localizer of BRCA2 (PALB2) in a patient with a late EwS relapse. Its impact on homologous recombination is demonstrated, and breast cancer risk is discussed.
Molly Mack, A. Carolina Tufino, Mohd Azrin Jamalruddin, Sreya Dey, Yinghong Pan, Elina Mukherjee, Jessica D. Daley, Julia Meade, Mahmoud Aarabi, Lisa Maurer, James Cooper, Kara A. Bernstein, Kelly M. Bailey   +12 more
wiley   +1 more source

Triafamone (AE 1887196) a new rice herbicide for Asia

Julius-Kühn-Archiv, 2012
Triafamone (approved ISO common name) is a new sulfonanilide herbicide discovered and developed by Bayer CropScience AG under the code number AE 1887196. Its mode of action is inhibition of the enzyme acetolactate synthase (ALS).
Sato, Yoshitaka, Hacker, Erwin, Shirakura, Shinichi, Rosinger, Christopher, Heibkes, Silke, Nakamura Shin   +5 more
doaj   +1 more source